Display options
Cite
Schüle JM, Bergkvist L, Håkansson L, et al. CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. J Transl Med. 2004;2(1):45doi: 10.1186/1479-5876-2-45.
Schüle, J. M., Bergkvist, L., Håkansson, L., Gustafsson, B., & Håkansson, A. (2004). CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. Journal of translational medicine, 2(1), 45. https://doi.org/10.1186/1479-5876-2-45
Schüle, Jana M, et al. "CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression." Journal of translational medicine vol. 2,1 (2004): 45. doi: https://doi.org/10.1186/1479-5876-2-45
Schüle JM, Bergkvist L, Håkansson L, Gustafsson B, Håkansson A. CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression. J Transl Med. 2004 Dec 21;2(1):45. doi: 10.1186/1479-5876-2-45. PMID: 15613231; PMCID: PMC545070.
Copy Download .nbib Format: NLM
Share it on

J Transl Med. 2004 Dec 21;2(1):45. doi: 10.1186/1479-5876-2-45.

CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-zeta chain expression.

Journal of translational medicine

Jana M Schüle, Leif Bergkvist, Leif Håkansson, Bertil Gustafsson, Annika Håkansson

Affiliations

  1. Department of Surgery, Central Hospital, SE-72189 Västerås, Sweden. [email protected].

PMID: 15613231 PMCID: PMC545070 DOI: 10.1186/1479-5876-2-45

Abstract

BACKGROUND: Immunosuppression is documented in several malignant diseases, including breast cancer. Subsequently, future therapeutic concepts might include immunological approaches. However, detailed knowledge about tumor immunogenicity and host immunoreactivity, and how to assess these adequately, is still limited. We studied CD28 and CD3-zeta expression in sentinel node biopsies (SNB) from breast cancer patients to analyze tumor-related changes in T cell activity. METHOD: 25 women underwent surgery for primary breast cancer, including SNB. Frozen sections from 21 sentinel nodes could be analyzed with a double-staining technique. CD28 expression was studied in CD4+ and CD8+ T-lymphocyte subsets and compared with CD3-zeta expression in three specified nodal regions. RESULTS: The degree of CD28 expression varied between the different lymph node areas. The lowest degree of CD28 expression was observed in CD4+ T-lymphocytes in the paracortex and germinal centers. Here, a good agreement with CD3-zeta expression was found. A higher CD28 expression was noted in CD4+ T-cells in the primary follicles, where concordance with CD3-zeta expression was weaker. The CD8+ T-lymphocyte subset displayed generally a higher degree of CD28 expression than the CD4+ subset. CONCLUSION: Sentinel lymph nodes from breast cancer patients displayed local immunosuppression of varying extent. In the areas with the lowest degree of CD28 expression an accordingly low CD3-zeta expression was found. The SNB might prove an important diagnostic tool for the evaluation of interactions between tumor and the host immune system, helping to select patients who might benefit from adjuvant immunotherapy.

References

  1. Int J Cancer. 2000 Oct 15;88(2):239-44 - PubMed
  2. Nature. 1992 Apr 16;356(6370):607-9 - PubMed
  3. Breast Cancer Res Treat. 2002 Jul;74(1):33-40 - PubMed
  4. J Immunol. 1995 Feb 1;154(3):985-97 - PubMed
  5. Cancer Immunol Immunother. 1999 Aug;48(5):253-62 - PubMed
  6. J Immunol. 1999 Jun 1;162(11):6572-9 - PubMed
  7. Semin Cancer Biol. 2001 Aug;11(4):285-95 - PubMed
  8. Crit Rev Oncog. 2000;11(2):97-133 - PubMed
  9. J Interferon Cytokine Res. 1998 Nov;18(11):927-37 - PubMed
  10. J Exp Med. 1994 Feb 1;179(2):523-32 - PubMed
  11. Eur J Immunol. 2001 Jan;31(1):138-45 - PubMed
  12. Cancer Immunol Immunother. 2002 Nov;51(9):499-504 - PubMed
  13. Clin Immunol. 1999 Dec;93(3):256-62 - PubMed
  14. Immunol Today. 1993 Oct;14(10):483-6 - PubMed
  15. Immunol Today. 1994 May;15(5):225-34 - PubMed
  16. Immunopharmacol Immunotoxicol. 2001 May;23(2):163-73 - PubMed
  17. Eur J Immunol. 2000 Dec;30(12):3699-706 - PubMed
  18. Res Immunol. 1995 Mar-Apr;146(3):140-9 - PubMed
  19. Immunol Today. 1994 Jul;15(7):321-31 - PubMed
  20. J Immunol. 1990 Mar 1;144(5):1646-53 - PubMed
  21. Immunol Res. 1996;15(1):38-49 - PubMed
  22. J Clin Invest. 1996 May 1;97(9):2027-37 - PubMed
  23. Int J Cancer. 1998 Sep 25;78(1):16-20 - PubMed
  24. Int J Cancer. 2001 Apr 1;92(1):96-105 - PubMed
  25. J Immunother. 2000 Nov-Dec;23(6):631-42 - PubMed
  26. Immunity. 1996 Jun;4(6):527-34 - PubMed
  27. Int J Clin Pract. 2002 May;56(4):261-6 - PubMed
  28. Int J Cancer. 1995 Jun 9;61(6):765-72 - PubMed
  29. Cytotherapy. 2000;2(4):287-95 - PubMed
  30. Leukemia. 1996 Mar;10(3):494-7 - PubMed
  31. Cancer Res. 1998 Dec 1;58(23):5344-7 - PubMed
  32. Eur J Immunol. 1997 Mar;27(3):598-608 - PubMed
  33. Blood. 2002 Nov 1;100(9):3155-63 - PubMed
  34. Cancer Immunol Immunother. 1999 Sep;48(6):336-41 - PubMed
  35. Int Immunol. 2001 Apr;13(4):441-50 - PubMed
  36. Int Immunol. 1992 Jun;4(6):661-71 - PubMed
  37. J Clin Epidemiol. 1993 May;46(5):423-9 - PubMed
  38. Eur J Immunol. 1998 Jul;28(7):2131-42 - PubMed
  39. Cell Immunol. 1998 Dec 15;190(2):141-55 - PubMed
  40. Immunol Today. 1990 Jun;11(6):211-6 - PubMed

Publication Types